Compare NXP Semiconductors N.V. Common Stock (NXPI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NXP Semiconductors N.V. Common Stock vs Organon & Co. Common Stock — how do they compare? NXP Semiconductors N.V. Common Stock trades at $218.49 (market cap $55.69B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 15.4× Organon & Co. Common Stock's market cap, and NXP Semiconductors N.V. Common Stock pays the higher dividend (1.84%). Which is the better fit depends on your goals — on Pluang, investors hold NXP Semiconductors N.V. Common Stock for 5 Days and Organon & Co. Common Stock for 0 Days on average.
| NXPI | OGN | |
|---|---|---|
Market Cap | $55.69B | $3.61B |
Volume | 4,397,771 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $332.67 | $13.81 |
52-Week Low | $184.19 | $5.70 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $63.80B | $11.03B |
Dividend Yield | 1.84% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.
NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NXP Semiconductors N.V. Common Stock
NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
